BSEGeneral3h ago · 18 Nov 2026, 07:03 pm

Outcome of Board Meeting pursuant to Regulation 30 of SEBI LODR, 2015 to consider and approve of financial restructuring , exploring strategic options and convening of EGM of the Company

Mangalam Drugs & Organics Ltd · 532637

✦ AI SummaryResults

Mangalam Drugs & Organics Ltd's board approved financial restructuring, exploring strategic options, and convening an EGM to seek approval for the proposed sale/disposal of its leasehold land rights and building. The proposal is at an exploratory stage, and no definitive agreement has been entered into. The expected date of completion is uncertain and will depend on identifying a suitable buyer, finalizing commercial terms, and obtaining requisite approvals.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk6/10
Balance Sheet Risk8/10
Liquidity Impact5/10
Market Sentiment4/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Mangalam Drugs & Organics Ltd - 532637 - Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of SEBI LODR, 2015

Attachments (1)

📄

235973e2-7b5a-47d2-be65-01e7ff305a54.pdf

pdf

Download →
View document text
Mangalam Drugs and Organics Limited Regd. Office : Rupam Building, 3rd Floor, 239 P. D’'Mello Road, NearG. P. O. Mumbai - 400 001 @ 91-22-62616200 / 6300 / 8787 @ 91-22-€ 2619090 o CIN : L24230MH1972PLC116413 REF: MDOL/CS-SE/2026-27/045 November 18", 2026 Listing Department Listing Department BSE Ltd National Stock Exchange of India 1* Floor, New Trade Wing, Limited Phiroze Jecjeebhoy Towers, “Exchange Plaza”, 5" Floor, Dalal Street, Fort, Plot No. C-1, Block G, Mumbai — 400 001 Bandra - Kurla Complex, Bandra(E), Mumbai — 400 051 Serip Code: 532637 Symbol: MANGALAM Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 —Proposal for Sale of Company’s undertaking. Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule 111 thereto, and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026 (Chapter V, Section V- A, read with Annexure 18 and Annexure 18A thereto), we wish to inform you that the Board of Directors of the Company, at its meeting held on Wednesday, 18" November, 2026, considered and approved the proposal for undertaking financial restructuring and exploring various strategic options for the Company, including the potential sale/disposal of the Company's leasehold land rights and building situated at Unit-2, Plot No. 1203, GIDC, Vapi, District Valsad, Gujarat —396195. In this regard, the Board has also approved convening the Extra-Ordinary General Meeting (EGM) of the Members of the Company for the financial year 2026-27 to scek their approval, wherever required under applicable laws, in respect of the proposed strategic options and to authorise the Board of Directors to take all necessary steps and actions in this regard. It is clarified that the proposal is presently at an exploratory stage and the Company has not entered into any definitive agreement or arrangement for the proposed sale/disposal. The identity of the prospective buyer(s), consideration, commercial terms and other transaction- related particulars shall be determined at an appropriate stage, subject to necessary approvals and compliance with applicable laws The relevant disclosures in respect of the proposed sale/disposal of the aforesaid undertaking, in accordance with Regulation 30 of the SEBI Listing Regulations, are enclosed herewith as Annexure-1. Factory : at Vapi (Gujarat) India ® cont ctus@mangalamdrugs.com @ http://www.mangalamdrugs.com Mangalam Drugs and Organics Limited % MANGALAM Regd: Office : Rupam Building, 3rd Floor, 239 P. D’Mello Road, Near G. P. . Mumbai - 400 001 -’ ® 91-22-62/6 613060 2/ 807807 @ 91-22-62619090 » CIN : 124230MH1972PLC116413 wHoe The aforesaid information shall also be made available on the Company's website at www.mangalamdrugs.com. The Meeting of the board of Directors of the Company commenced at 02:30 p.m. and concluded at 05:00 p.m. Kindly take the same on record. Thanking you, For Mangalam Drugs and Organics Limited Govardhan Murlidhar Dhoot Managing Director DIN: 01240086 Factory : at Vapi (Gujarat) India ® contactus@mangalamdrugs.com @ http://www.mangalamdrugs.com Mangalam Drugs and Organics Limited MANGALAM Hvrd Office : Rupam Building, 3rdF\ oor 239 P. D' M(“O R( ad, Near G. P. 0. Mumbai - 400 001 @ 91-22-62/ 663010 6/ 827807 0@ 9 1- 22-62619090o CIN : L24230MH1972PLC116413 ANNEXURE-1 CONTINUOUS DISCLOSURE UNDER SUB-PARA 1 OF PARA A OF PART A OF SCHEDULE I PURSUANT TO REGULATION 30 OF THE SEBI (LODR) REGULATION, 2015 Particulars of the proposed sale/disposal of leasehold land rights and building situated at Unit-2, Plot No. 1203, GIDC, Vapi, District Valsad, Gujarat — 396195 ]i:;' Particulars Details 1 | The amount and || Sr no | Particulars Amount % percentage of the turnover Rsin or revenue or income and || er net worth contributed by ||1 . Revenue/Turnover 74.46 cr 32% such unit or division or ||2 . Total Income T446cr [32% undertaking or subsidiary || 3. Net worth = - or associate company of the listed entity during the [The Revenue / Total Income of listed Entity is 232.90cr. last financial year; 2 Date on which the | Not Applicable at this stage, as the proposal is presently at agreement for sale has | an exploratory stage and no definitive agreement for been entered into; ‘ sale/disposal has been entered into by the Company. 3 The expected date | The expected date of completion of the proposed of completion of sale/disposal is presently not ascertainable and shall depend | sale/disposal: upon the identification of a suitable prospective buyer, | finalisation of commercial terms and receipt of requisite statutory, regulatory and shareholders' approvals, wherever applicable. i Consideration The consideration receivable, if any, has not yet been received/receivable from | determined, as the proposal is at an exploratory stage and such sale/ disposal; no valuation or definitive commercial terms have been finalized. 5 Brief details of buycr(s)fi Not Applicable at this stage, as no prospective buyer has and whether the buyers | been identified or finalised by the Company. The requisite belongs to the | details shall be disclosed upon identification and promoter/promoter finalisation of the prospective buyer, in accordance with group/group companies. If | applicable regulatory requirements. yes, details thereof; Factory : at Vapi (Gujarat) India @ contactus@mangalamdrugs.com @ http;//www.mangalamdrugs.com Mangalam Drugs and Organics Limited f Regd. Office : Rupam Building, 3rd Floor, 239 P. D’M(:Ho‘Rmd, Near G. P. 0. Mumbai - 400 001 ® 91-22-62616200 / 63/0 87087 & 91-22-62619090 CIN : L24230MH1972PLC116413 | Accredited Whether the transaction The applicability of related party transaction provisions would fall within related shall be examined upon identification of the prospective party transactions? If yes, buyer and finalisation of the proposed transaction. If the whether the same is done proposed transaction constitutes a Related Party at “arm’s length™; Transaction, the same shall be undertaken subject to the requisite approvals and compliance with applicable provisions of the Companies Act, 2013 and SEBI Listing Regulations, including the requirement of being on an arm's length basis, wherever applicable. Whether the sale, lease or The proposed sale/disposal is presently being explored disposal oft he undertaking independently and is not contemplated as part of any is outside Scheme of Scheme of Arrangement. The applicability of Regulation Arrangement? If yes, 37A of the SEBI Listing Regulations and other applicable details of the same provisions shall be examined based on the final structure including compliance with and terms of the proposed transaction. The Company shall regulation 37A of LODR obtain the requisite shareholders' approval and comply with Regulations. all applicable regulatory requirements, including Regulation 37A, wherever applicable, before undertaking the proposed sale/disposal Additionally. in case of a Not Applicable at this stage, as the proposal is presently at slump sale, indicative an exploratory stage and no decision has been taken disclosures provided for regarding the structure or mode of the proposed transaction, amalgamation/merger, including whether the same would be undertaken by way of shall be disclosed by the a slump sale. listed entity with respect to such slump sale. For Mangalam Drugs and Organics Limited Govardhan Murlidhar Dhoot Managing Director DIN: 01240086 Factory : at Vapi (Gujarat) India @ contactus@mangalamdrugs.com @ http://www.mangalamdrugs.com